- Single-domain antibody
A single-domain antibody (sdAb, called Nanobody by Ablynx, the developer) is an antibody fragment consisting of a single monomeric variable antibody domain. Like a whole antibody, it is able to bind selectively to a specific antigen. With a molecular weight of only 12–15 kDa, single-domain antibodies are much smaller than common antibodies (150–160 kDa) which are composed of two heavy protein chains and two light chains, and even smaller than Fab fragments (~50 kDa, one light chain and half a heavy chain) and single-chain variable fragments (~25 kDa, two variable domains, one from a light and one from a heavy chain).
The first single-domain antibodies were engineered from heavy-chain antibodies found in camelids; these are called VHH fragments. Cartilaginous fishes also have heavy-chain antibodies (IgNAR, 'immunoglobulin new antigen receptor'), from which single-domain antibodies called VNAR fragments can be obtained. An alternative approach is to split the dimeric variable domains from common immunoglobulin G (IgG) from humans or mice into monomers. Although most research into single-domain antibodies is currently based on heavy chain variable domains, nanobodies derived from light chains have also been shown to bind specifically to target epitopes.
A single-domain antibody is a peptide chain of about 110 amino acids long, comprising one variable domain (VH) of a heavy-chain antibody, or of a common IgG. These peptides have similar affinity to antigens as whole antibodies, but are more heat-resistant and stable towards detergents and high concentrations of urea. Those derived from camelid and fish antibodies are less lipophilic and better soluble in water, owing to their complementarity determining region 3 (CDR3), which forms an extended loop (coloured orange in the ribbon diagram above) covering the lipophilic site that normally binds to a light chain. In contrast to common antibodies, two out of six single-domain antibodies survived a temperature of 90 °C (194 °F) without losing their ability to bind antigens in a 1999 study. Stability towards gastric acid and proteases depends on the amino acid sequence. Some species have been shown to be active in the intestine after oral application, but their low absorption from the gut impedes the development of systemically active single-domain antibodies.
The comparatively low molecular mass leads to a better permeability in tissues, and to a short plasma half-life since they are eliminated renally. Unlike whole antibodies, they do not show complement system triggered cytotoxicity because they lack an Fc region. Camelid and fish derived sdAbs are able to bind to hidden antigens that are not accessible to whole antibodies, for example to the active sites of enzymes. This property has been shown to result from their extended CDR3 loop, which is able to penetrate such sites.
From heavy-chain antibodies
A single-domain antibody can be obtained by immunization of dromedaries, camels, llamas, alpacas or sharks with the desired antigen and subsequent isolation of the mRNA coding for heavy-chain antibodies. By reverse transcription and polymerase chain reaction, a gene library of single-domain antibodies containing several million clones is produced. Screening techniques like phage display and ribosome display help to identify the clones binding the antigen.
A different method uses gene libraries from animals that have not been immunized beforehand. Such naïve libraries usually contain only antibodies with low affinity to the desired antigen, making it necessary to apply affinity maturation by random mutagenesis as an additional step.
When the most potent clones have been identified, their DNA sequence is optimized, for example to improve their stability towards enzymes. Another goal is humanization to prevent immunological reactions of the human organism against the antibody. Humanization is unproblematic because of the homology between camelid VHH and human VH fragments. The final step is the translation of the optimised single-domain antibody in E. coli, Saccharomyces cerevisiae or other suitable organisms.
From conventional antibodies
Alternatively, single-domain antibodies can be made from common murine or human IgG with four chains. The process is similar, comprising gene libraries from immunized or naïve donors and display techniques for identification of the most specific antigens. A problem with this approach is that the binding region of common IgG consists of two domains (VH and VL), which tend to dimerize or aggregate because of their lipophilicity. Monomerization is usually accomplished by replacing lipophilic by hydrophilic amino acids, but often results in a loss of affinity to the antigen. If affinity can be retained, the single-domain antibodies can likewise be produced in E. coli, S. cerevisiae or other organisms.
Orally available single-domain antibodies against E. coli-induced diarrhoea in piglets have been developed and successfully tested. Other diseases of the gastrointestinal tract, such as inflammatory bowel disease and colon cancer, are also possible targets for orally available sdAbs.
ALX-0081, a single-domain antibody targeting von Willebrand factor is in clinical trials for the prevention of thrombosis in patients with acute coronary syndrome. A Phase II study examining ALX-0081 in high risk percutaneous coronary intervention has started in September 2009.
Ablynx expects that their Nanobodies might cross the blood-brain barrier and permeate into large solid tumours more easily than whole antibodies, which would allow for the development of drugs against brain cancers.
- ^ Gibbs, W. Wayt (August 2005). "Nanobodies". Scientific American Magazine. http://www.sciam.com/article.cfm?chanID=sa006&articleID=0004C949-F886-12DB-B88683414B7F0000.
- ^ a b Harmsen MM, De Haard HJ (November 2007). "Properties, production, and applications of camelid single-domain antibody fragments". Appl. Microbiol. Biotechnol. 77 (1): 13–22. doi:10.1007/s00253-007-1142-2. PMC 2039825. PMID 17704915. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2039825.
- ^ Möller, A.; Pion, E; Narayan, V; Ball, KL (September 2010). "Intracellular activation of interferon regulatory factor-1 by nanobodies to the multi-functional (Mf1) domain". The Journal of biological chemistry (J Biol Chem) 285 (49): 38348–38361. doi:10.1074/jbc.M110.149476. PMC 2992268. PMID 20817723. http://www.jbc.org/content/early/2010/09/03/jbc.M110.149476.abstract.
- ^ "Nanobodies herald a new era in cancer therapy". The Medical News. 12 May 2004. http://www.news-medical.net/?id=1477.
- ^ "Pipeline". Ablynx. http://www.ablynx.com/research/pipeline.htm. Retrieved 20 January 2010.
- ^ a b Dolk, E.; Van Der Vaart, M.; Lutje Hulsik, D.; Vriend, G.; De Haard, H.; Spinelli, S.; Cambillau, C.; Frenken, L. et al. (2005). "Isolation of Llama Antibody Fragments for Prevention of Dandruff by Phage Display in Shampoo". Applied and Environmental Microbiology 71 (1): 442–450. doi:10.1128/AEM.71.1.442-450.2005. PMC 544197. PMID 15640220. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=544197.
- ^ a b Stanfield, R.; Dooley, H.; Flajnik, M.; Wilson, I. (2004). "Crystal structure of a shark single-domain antibody V region in complex with lysozyme". Science 305 (5691): 1770–1773. Bibcode 2004Sci...305.1770S. doi:10.1126/science.1101148. PMID 15319492.
- ^ Van Der Linden, R.; Frenken, L.; De Geus, B.; Harmsen, M.; Ruuls, R.; Stok, W.; De Ron, L.; Wilson, S. et al. (1999). "Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies". Biochimica et Biophysica Acta 1431 (1): 37–46. doi:10.1016/S0167-4838(99)00030-8. PMID 10209277.
- ^ Harmsen, M. .; Vansolt, C. .; Hoogendoorn, A. .; Vanzijderveld, F. .; Niewold, T. .; Vandermeulen, J. . (2005). "Escherichia coli F4 fimbriae specific llama single-domain antibody fragments effectively inhibit bacterial adhesion in vitro but poorly protect against diarrhoea". Veterinary Microbiology 111 (1–2): 89. doi:10.1016/j.vetmic.2005.09.005. PMID 16221532.
- ^ a b Harmsen, M. M.; Solt, C. B.; Zijderveld-Van Bemmel, A. M.; Niewold, T. A.; Zijderveld, F. G. (2006). "Selection and optimization of proteolytically stable llama single-domain antibody fragments for oral immunotherapy". Applied Microbiology and Biotechnology 72 (3): 544–551. doi:10.1007/s00253-005-0300-7. PMID 16450109.
- ^ Desmyter, A.; Transue, T. R.; Ghahroudi, M. A.; Thi, M. H.; Poortmans, F.; Hamers, R.; Muyldermans, S.; Wyns, L. (1996). "Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme". Nature structural biology 3 (9): 803–811. doi:10.1038/nsb0996-803. PMID 8784355.
- ^ Arbabi Ghahroudi, M.; Desmyter, A.; Wyns, L.; Hamers, R.; Muyldermans, S. (1997). "Selection and identification of single domain antibody fragments from camel heavy-chain antibodies". FEBS letters 414 (3): 521–526. doi:10.1016/S0014-5793(97)01062-4. PMID 9323027.
- ^ a b Saerens, D.; Ghassabeh, G.; Muyldermans, S. (2008). "Single-domain antibodies as building blocks for novel therapeutics". Current Opinion in Pharmacology 8 (5): 600–608. doi:10.1016/j.coph.2008.07.006. PMID 18691671.
- ^ Holt, L. J.; Herring, C.; Jespers, L. S.; Woolven, B. P.; Tomlinson, I. M. (2003). "Domain antibodies: proteins for therapy". Trends in biotechnology 21 (11): 484–490. doi:10.1016/j.tibtech.2003.08.007. PMID 14573361.
- ^ Borrebaeck, C. A. K.; Ohlin, M. (2002). "Antibody evolution beyond Nature". Nature Biotechnology 20 (12): 1189. doi:10.1038/nbt1202-1189. PMID 12454662.
- ^ a b "Nanobodies". Nanobody.org. 2006. http://www.nanobody.org.
- ^ "Ablynx Announces Interim Results of First Nanobody Phase I Study of,ALX-0081 (ANTI-VWF)". Bio-Medicine.org. 2 July 2007. http://www.bio-medicine.org/medicine-technology/Ablynx-Announces-Interim-Results-of-First-Nanobody-Phase-I-Study-of-0AALX-0081--28ANTI-VWF-29-135-1.
- ^ ClinicalTrials.gov NCT01020383 Comparative Study of ALX-0081 Versus GPIIb/IIIa Inhibitor in High Risk Percutaneous Coronary Intervention (PCI) Patients
Engineered monoclonal antibodies and antibody mimetics Whole antibodybispecific: Trifunctional antibody Fab fragment Variable fragmentSingle-chain variable fragment / di-scFv / tri-scFv • Single-domain antibody • Small modular immunopharmaceutical • bispecific: T-cell engager Smaller units IntracellularIntrabody Antibody mimetics
Wikimedia Foundation. 2010.
Look at other dictionaries:
single domain antibody — See: dAb … Glossary of Biotechnology
Antibody — Immunoglobulin redirects here. For the immunoglobulin family, see Immunoglobulin superfamily. Antibodies redirects here. For the film, see Antibodies (film). Each antibody binds to a specific antigen; an interaction similar to a lock and key. An… … Wikipedia
Single-chain variable fragment — Rotating scFv fragment with highlighted complementary determining regions (CDRs) … Wikipedia
Single chain variable fragment — (scFv) is a fusion of the variable regions of the heavy and light chains of immunoglobulins, linked together with a short (usually serine, glycine) linker.This chimeric molecule retains the specificity of the original immunoglobulin, despite… … Wikipedia
Protein domain — Pyruvate kinase, a protein from three domains (PDB 1pkn) A protein domain is a part of protein sequence and structure that can evolve, function, and exist independently of the rest of the protein chain. Each domain forms a compact three… … Wikipedia
Monobody — The tenth fibronectin type III domain (human, PDB 1TTG) … Wikipedia
Einzeldomänenantikörper — Strukturmodel eines Einzeldomänenantikörpers (Bändermodell). Einzeldomänenantikörper, auch Nanobodys oder Nanoantikörper genannt, sind Antikörperfragmente, die aus einer einzelnen, monomeren variablen Domäne eines Antikörpers aufgebaut sind. Im… … Deutsch Wikipedia
Monoclonal antibodies — A general representation of the methods used to produce monoclonal antibodies. Monoclonal antibodies (mAb or moAb) are monospecific antibodies that are the same because they are made by identical immune cells that are all clones of a unique… … Wikipedia
DARPin — A DARPin with four ankyrin repeat motifs (PDB 1N0R) DARPins (an acronym for designed ankyrin repeat proteins) are genetically engineered antibody mimetic proteins typically exhibiting highly specific and high affinity target protein binding. They … Wikipedia
Microantibody — A microantibody is an artificial short chain of amino acids copied from a fully functional natural antibody. Microantibodies can stop viruses such as HIV infecting cells in vitro. Antibodies are produced naturally by the body and play a key… … Wikipedia